GHRH analog (growth-hormone-releasing) · FDA-approved (Egrifta, HIV lipodystrophy)
An FDA-approved growth-hormone-releasing peptide proven to cut visceral belly fat in HIV-associated lipodystrophy, but not approved for general weight loss or anti-aging.
✦ 2 min read · 2 sourcesWhat it is
Tesamorelin (brand Egrifta / Egrifta SV) is a stabilized growth-hormone-releasing hormone (GHRH) analog. The FDA approved it in 2010 specifically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved for general weight loss, bodybuilding, anti-aging, or non-HIV metabolic conditions.
How it works
Tesamorelin binds the GHRH receptor and stimulates the body's own pituitary release of growth hormone, raising IGF-1 in a more physiologic, pulsatile way than injecting growth hormone directly. The resulting GH/IGF-1 signaling preferentially reduces visceral (deep abdominal) adipose tissue.
What the evidence shows
Two pooled phase 3 trials (about 806 participants, including women) showed roughly 15% reduction in visceral adipose tissue versus placebo at 26 weeks, with improvements in triglycerides. Later randomized trials in people with HIV also showed meaningful reductions in liver fat. Evidence in non-HIV populations is smaller and preliminary, so broader metabolic and women's-wellness claims are not yet established.
Quick check
Four questions, ~60 seconds, with a sourced result.
The honest take
FDA-approved with strong trial data for one specific population (HIV-associated visceral fat); broader metabolic and women's-wellness use is off-label and less proven.
Status & safety
Tesamorelin is a prescription drug; legitimate access is via a prescriber for the approved indication. Labeled cautions include raised IGF-1 (with theoretical concern about cell growth), fluid retention, joint pain, glucose/insulin changes, and contraindications such as active malignancy and pregnancy. Research- or gray-market 'tesamorelin' for fat loss or anti-aging is outside the approved use and not quality-assured.
Summaries of published, third-party research for educational purposes. Not medical advice; not a claim of efficacy or safety for any use.
New, plain-language summaries as the literature develops. Educational only — no products, nothing for sale.
Melanocortin receptor agonist · FDA-approved (Vyleesi, 2019)
An FDA-approved, as-needed injection that acts on brain melanocortin pathways to raise sexual desire in certain premenopausal women, with real but modest effect sizes.
Read more →Endogenous neuropeptide hormone · FDA-approved (IV/IM obstetrics); intranasal investigational
A natural hormone that is FDA-approved for labor and proven in milk let-down, but whose intranasal use for mood, bonding, or libido remains investigational and mixed.
Read more →Copper-binding signal peptide · Cosmetic ingredient (topical); not an approved drug
A naturally occurring copper-binding peptide used in topical skincare, with small human trials suggesting improvements in skin firmness and fine lines.
Read more →